Literature DB >> 29432613

Circulating Dkk1 and TRAIL Are Associated With Cognitive Decline in Community-Dwelling, Older Adults With Cognitive Concerns.

Ryan D Ross1, Raj C Shah2,3, Sue Leurgans3,4, Teodoro Bottiglieri5, Robert S Wilson3,4,6, Dale Rick Sumner1,7.   

Abstract

Background: Osteoporosis and Alzheimer's disease are common diseases of aging that would seem to be unrelated, but may be linked through the influence of bone-derived signals on brain function. The aim of the current study is to investigate the relationship between circulating levels of bone-related biomarkers and cognition.
Methods: The population included 103 community-dwelling older individuals with memory concerns but without cognitive impairment. A global cognition summary measure was collected at baseline and 6, 12, and 18 months post-enrollment by converting raw scores from 19 cognitive function tests to z-scores and averaging. Baseline plasma concentrations of bone-related biomarkers, including undercarboxylated, carboxylated, and total osteocalcin, parathyroid hormone, C-terminal telopeptide of collagen 1 (CTX-1), procollagen type 1 amino-terminal propeptide, osteoprotegrin, osteopontin, Dickkopf WNT signaling pathway inhibitor 1 (Dkk1), sclerostin, and amyloid β peptides (Aβ40 and Aβ42), were measured.
Results: Using sex, age, and education-adjusted mixed-effects models, we found that baseline levels of TNF-related apoptosis-inducing ligand (TRAIL; p < .001), Dkk1 (p = .014), and CTX-1 (p = .046) were related to the annual rate of change of global cognition over the 18 month follow-up. In cognitive domain-specific analysis, baseline TRAIL was found to be positively related to the annual rate of change in episodic (p < .001) and working memory (p = .016), and baseline Dkk1 was positively related to semantic memory (p = .027) and negatively related to working memory (p = .016). Conclusions: These results further confirm the link between bone and brain health and suggest that circulating levels of bone-related biomarkers may have diagnostic potential to predict worsening cognition.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29432613      PMCID: PMC6230213          DOI: 10.1093/gerona/glx252

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  47 in total

1.  TRAIL is expressed in the brain cells of Alzheimer's disease patients.

Authors:  Daniela Uberti; Giuseppina Cantarella; Fabio Facchetti; Alessia Cafici; Giuseppe Grasso; Renato Bernardini; Maurizio Memo
Journal:  Neuroreport       Date:  2004-03-22       Impact factor: 1.837

2.  Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.

Authors:  Ferry Sandra; Laifa Hendarmin; Seiji Nakamura
Journal:  Oral Oncol       Date:  2006-01-18       Impact factor: 5.337

3.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

Authors:  J G Emery; P McDonnell; M B Burke; K C Deen; S Lyn; C Silverman; E Dul; E R Appelbaum; C Eichman; R DiPrinzio; R A Dodds; I E James; M Rosenberg; J C Lee; P R Young
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

4.  Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.

Authors:  Daniela Uberti; Giulia Ferrari-Toninelli; Sara Anna Bonini; Ilenia Sarnico; Marina Benarese; Marina Pizzi; Luisa Benussi; Roberta Ghidoni; Giuliano Binetti; PierFranco Spano; Fabio Facchetti; Maurizio Memo
Journal:  Neuropsychopharmacology       Date:  2006-08-16       Impact factor: 7.853

Review 5.  Wnt signaling function in Alzheimer's disease.

Authors:  G V De Ferrari; N C Inestrosa
Journal:  Brain Res Brain Res Rev       Date:  2000-08

6.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

7.  Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline.

Authors:  Désirée R M Seib; Nina S Corsini; Kristina Ellwanger; Christian Plaas; Alvaro Mateos; Claudia Pitzer; Christof Niehrs; Tansu Celikel; Ana Martin-Villalba
Journal:  Cell Stem Cell       Date:  2013-02-07       Impact factor: 24.633

8.  Endocrine regulation of energy metabolism by the skeleton.

Authors:  Na Kyung Lee; Hideaki Sowa; Eiichi Hinoi; Mathieu Ferron; Jong Deok Ahn; Cyrille Confavreux; Romain Dacquin; Patrick J Mee; Marc D McKee; Dae Young Jung; Zhiyou Zhang; Jason K Kim; Franck Mauvais-Jarvis; Patricia Ducy; Gerard Karsenty
Journal:  Cell       Date:  2007-08-10       Impact factor: 41.582

9.  Individual differences in rates of change in cognitive abilities of older persons.

Authors:  Robert S Wilson; Laurel A Beckett; Lisa L Barnes; Julie A Schneider; Julie Bach; Denis A Evans; David A Bennett
Journal:  Psychol Aging       Date:  2002-06

Review 10.  Memory loss in Alzheimer's disease.

Authors:  Holger Jahn
Journal:  Dialogues Clin Neurosci       Date:  2013-12       Impact factor: 5.986

View more
  10 in total

1.  Brief Report: Undercarboxylated Osteocalcin Is Associated With Cognition in Women With and Without HIV.

Authors:  Ryan D Ross; Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Anjali Sharma; Kathleen M Weber; Audrey L French; Heather McKay; Phyllis C Tien; Michael T Yin; Leah H Rubin
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

Review 2.  Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer's Disease Complicated With Osteoporosis.

Authors:  Weifan Xu; Yiping Jiang; Nani Wang; Huanhuan Bai; Shengyan Xu; Tianshuang Xia; Hailiang Xin
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

3.  RANK/RANKL/OPG axis genes relation to cognitive impairment in children with transfusion-dependent thalassemia: a cross-sectional study.

Authors:  Suzan Omar Mousa; Asmaa Hosni Abd El-Hafez; Mostafa Ahmed Abu El-Ela; Mohamed Aboul-Fotouh Mourad; Rasha Nady Saleh; Samira Zain Sayed
Journal:  BMC Pediatr       Date:  2022-07-20       Impact factor: 2.567

4.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 5.  The Clinical Diagnostic and Prognostic Value of Dickkopf-1 in Cancer.

Authors:  Jie Li; Yan Gao; Wentao Yue
Journal:  Cancer Manag Res       Date:  2020-06-08       Impact factor: 3.989

6.  Elevations in Serum Dickkopf-1 and Disease Progression in Community-Dwelling Older Adults With Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease.

Authors:  Laura Tay; Bernard Leung; Audrey Yeo; Mark Chan; Wee Shiong Lim
Journal:  Front Aging Neurosci       Date:  2019-10-15       Impact factor: 5.750

Review 7.  Insight into the divergent role of TRAIL in non-neoplastic neurological diseases.

Authors:  Shiqi Gao; Yuanjian Fang; Sheng Tu; Huaijun Chen; Anwen Shao
Journal:  J Cell Mol Med       Date:  2020-08-22       Impact factor: 5.310

Review 8.  Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities.

Authors:  Jiaqi Liu; Qing Xiao; Jiani Xiao; Chenxi Niu; Yuanyuan Li; Xiaojun Zhang; Zhengwei Zhou; Guang Shu; Gang Yin
Journal:  Signal Transduct Target Ther       Date:  2022-01-03

Review 9.  Osteocalcin-A Versatile Bone-Derived Hormone.

Authors:  Sarah C Moser; Bram C J van der Eerden
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-10       Impact factor: 5.555

10.  Associations of Bone Turnover Markers with Cognitive Function in Patients Undergoing Hemodialysis.

Authors:  Ping-Hsun Wu; Yi-Ting Lin; Cheng-Sheng Chen; Yi-Wen Chiu; Jer-Chia Tsai; Po-Lin Kuo; Ya-Ling Hsu; Östen Ljunggren; Bengt Fellström; Mei-Chuan Kuo
Journal:  Dis Markers       Date:  2020-04-21       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.